Publications by authors named "Valerie Daix"
Diab Vasc Dis Res
November 2014
Article Synopsis
- GFT505 is a novel medication targeting liver receptors that showed effectiveness in reducing blood sugar levels and improving insulin sensitivity in diabetic mice.
- Unlike traditional diabetes medications like rosiglitazone, GFT505 did not cause any negative effects on heart health after long-term use in monkeys.
- Overall, GFT505 has a better safety profile and effectively addresses various aspects of type 2 diabetes without the cardiac side effects seen with other treatments.
